BofA analyst Chi Fong raised the firm’s price target on Roivant Sciences (ROIV) to $29.50 from $29 and keeps a Neutral rating on the shares. The firm’s new target reflects “un-risk-adjusting” its brepocitinib forecast given that the drug was granted a priority view and proximity to its FDA action date in Q3, the analyst tells investors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ROIV:
- SiTime, Photronics, Icici, Roivant, Marqeta Shake Markets
- Roivant Sciences participates in a conference call with JPMorgan
- Roivant Sciences assumed with an Overweight at Piper Sandler
- Roivant Sciences price target raised to $34 from $30 at Jefferies
- Roivant Advances Brepocitinib Program, Refocuses Autoimmune Portfolio